We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Allergan will pay $250 million to acquire the worldwide rights to two of Merck’s investigational small molecule oral calcitonin gene-related peptide (CGRP) antagonists for use against migraines. Read More
AstraZeneca and Cephalon have agreed to pay $54 million, plus interest, to settle allegations that they knowingly underpaid quarterly rebates owed to states under the Medicaid program. Read More
After nearly 25 years of trying to reach biologics manufacturer Chembiomed but getting no response, the FDA today revoked the Canadian firm’s license. Read More
Public health advocates called on the FDA Wednesday to expand access to the opioid overdose reversal drug naloxone by converting it from prescription-only to over-the-counter status. Read More
Public health advocates called on the FDA Wednesday to expand access to the opioid overdose reversal drug naloxone by converting it from prescription-only to over-the-counter status. Read More